Carlos A. Larrauri

I am a Visiting Researcher within the Neuroscience, Society and Ethics group (NEUROSEC), working under the supervision of Professor Ilina Singh. My current research, conducted as a Bates Overseas Fellow, is a qualitative pilot study examining how UK institutions operationalize Patient and Public Involvement (PPI) in the governance of artificial intelligence systems for mental health care. The study's primary question asks how these practices align—or diverge—from aspirational policy frameworks, and what lessons the UK model might offer for jurisdictions such as the United States. My broader scholarly interests lie at the intersection of law, health policy, bioethics, and mental health, with a particular focus on epistemic justice, the governance of emerging health technologies, and the integration of lived experience into research and regulatory processes. My work has appeared in World Psychiatry, Nature Mental Health, Schizophrenia, Psychiatric Services, JMIR Mental Health, and Early Intervention in Psychiatry, and has also been published by Cambridge University Press and the American Psychiatric Association.

I hold a JD from the University of Michigan Law School, where I served as a Senior Editor of the Michigan Law Review, and an MPA from the Harvard Kennedy School of Government, completed concurrently as a Zuckerman Fellow at the Center for Public Leadership. I also hold an MSN from the University of Miami School of Nursing and Health Studies and am board-certified as a family nurse practitioner and psychiatric-mental health nurse practitioner. I am a faculty member in the Executive and Continuing Education program at the Harvard T.H. Chan School of Public Health and serve as Co-chair of the Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ), a $117.7 million public-private partnership dedicated to advancing earlier and more effective treatment for individuals at clinical high risk for psychosis. I have previously served on the Board of Directors of the National Alliance on Mental Illness and have collaborated with the National Academies of Sciences, Engineering, and Medicine, the Broad Institute's Psychiatric Biomarkers Network, and the Healthy Brains Global Initiative.